Arbutus Biopharma (ABUS) Capital Expenditures (2013 - 2024)

Arbutus Biopharma has disclosed Capital Expenditures across 12 years of filings, most recently posting $86000.0 for Q4 2024.

• Capital Expenditures for Q4 2024 came in at $86000.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $86000.0 (down 10.42% YoY), and the FY2024 annual result was $182000.0, down 81.94% from the prior year.
• Capital Expenditures came in at $86000.0 for Q4 2024 at Arbutus Biopharma, up from $1000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $859000.0 in Q2 2023 to a low of $1000.0 in Q2 2024.
• The 5-year median for Capital Expenditures is $91000.0 (2022), against an average of $161176.5.
• Across the five-year window, Capital Expenditures soared 857.58% in 2021 and tumbled 99.88% in 2024, its largest moves.
• Arbutus Biopharma's Capital Expenditures stood at $152000.0 in 2020, then plunged by 61.84% to $58000.0 in 2021, then surged by 131.03% to $134000.0 in 2022, then sank by 76.12% to $32000.0 in 2023, then jumped by 168.75% to $86000.0 in 2024.
• The last three Capital Expenditures figures came in at $86000.0 (Q4 2024), $1000.0 (Q2 2024), and $95000.0 (Q1 2024), per Business Quant data.